Organogenesis (NASDAQ:ORGO) Stock Dropped to Strong Sell by Wall Street Zen

Organogenesis (NASDAQ:ORGO - Get Free Report) was downgraded by research analysts at Wall Street Zen from a "sell" rating to a "strong sell" rating in a report released on Sunday, Wall Street Zen reports.

Several other research analysts also recently commented on ORGO. Weiss Ratings raised Organogenesis from a "sell (e+)" rating to a "sell (d-)" rating in a report on Monday, November 9th. Truist Financial dropped their price target on Organogenesis from $3.00 to $2.00 and set a "hold" rating for the company in a report on Friday, August 7th. Two equities research analysts have rated the stock with a Hold rating and one has assigned a Sell rating to the company's stock. Based on data from MarketBeat.com, the stock has a consensus rating of "Reduce" and an average target price of $4.33.

Organogenesis Price Performance

Shares of Organogenesis stock traded down $0.15 during mid-day trading on Friday, reaching $0.81. 686,454 shares of the stock were exchanged, compared to its average volume of 1,218,365. The company has a market cap of $105.15 million, a price-to-earnings ratio of -0.66 and a beta of 1.48. The company has a current ratio of 3.32, a quick ratio of 2.76 and a debt-to-equity ratio of 0.09. The firm has a 50-day simple moving average of $1.19 and a 200 day simple moving average of $2.23. Organogenesis has a fifty-two week low of $0.73 and a fifty-two week high of $6.32.

Organogenesis (NASDAQ:ORGO - Get Free Report) last released its quarterly earnings results on Thursday, November 5th. The company reported ($0.25) EPS for the quarter, missing analysts' consensus estimates of ($0.18) by ($0.07). The firm had revenue of $45.46 million during the quarter, compared to analyst estimates of $52.10 million. Organogenesis had a negative net margin of 39.34% and a negative return on equity of 55.28%.

Institutional Investors Weigh In On Organogenesis

A number of hedge funds have recently added to or reduced their stakes in the stock. BlackRock Inc. acquired a new stake in shares of Organogenesis during the 2nd quarter worth approximately $17,616,000. Deutsche Bank AG bought a new stake in shares of Organogenesis during the second quarter worth approximately $4,146,000. Bank of America Corp DE bought a new stake in shares of Organogenesis during the second quarter worth approximately $1,368,000. Bank of New York Mellon Corp acquired a new position in Organogenesis in the second quarter valued at approximately $777,000. Finally, Renaissance Technologies LLC lifted its holdings in Organogenesis by 30.5% in the first quarter. Renaissance Technologies LLC now owns 1,068,538 shares of the company's stock valued at $2,532,000 after buying an additional 249,838 shares during the period. Institutional investors own 49.57% of the company's stock.

Organogenesis Company Profile

Organogenesis Holdings Inc. is a regenerative medicine company that develops, manufactures and commercializes products for advanced wound care and surgical and sports medicine. The company's products are designed to support tissue repair and healing in a range of clinical settings. Its portfolio includes wound-care products such as Apligraf, a bioengineered skin substitute, and products made from or incorporating materials including placental tissue and purified collagen. Organogenesis also offers products for surgical and sports medicine applications.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.